Cingulate Inc. (NASDAQ: CING)

Cingulate Inc., a biopharmaceutical company (NASDAQ: CING), is dedicated to developing and commercializing innovative pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform technology. The company's primary focus is on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and anxiety, with a pipeline of product candidates designed to improve patient compliance and health outcomes.

Cingulate's PTR platform technology allows for the release of drug substances at specific, pre-defined time intervals, enabling once-daily dosing and eliminating the need for booster or recovery doses. This technology has the potential to provide significant advantages over currently available ADHD treatments, including faster onset of action, minimized or eliminated crash/rebound effects, and entire active-day efficacy.

The company's lead product candidate, CTx-1301, is a stimulant medication designed to treat ADHD. It has completed a Phase 1/2 study, which demonstrated tolerability, comparative bioavailability, and dose proportionality compared to Focalin XR. A Phase 3 adult dose-optimization study was initiated in December 2022 and completed in June 2023, with results presented at the 2024 American Professional Society of ADHD and Related Disorders (APSARD) meeting. The company plans to submit a New Drug Application (NDA) for CTx-1301 in the first half of 2025 under the Section 505(b)(2) pathway.

Cingulate is also developing CTx-1302, a second investigational asset for the treatment of ADHD, which is expected to initiate a clinical plan in 2025 pending additional capital resources. Additionally, the company is advancing the development of CTx-2103, a product candidate for the treatment of anxiety, which has completed a formulation study demonstrating the ability to deliver a single administration of triple-release buspirone.

The company's PTR platform technology has the potential to be applied to other therapeutic areas, including insomnia, non-opioid pain, Alzheimer's, hypothyroidism, psychosis, depression, cardiovascular disorders, Parkinson's disease, migraine, oral oncology, xerostomia (dry mouth), and bipolar disorder, among others.

Cingulate's management team has extensive experience in the biopharmaceutical industry, with a strong track record of developing and commercializing pharmaceutical products. The company's founders and management team have held senior leadership roles at leading biopharmaceutical companies, including Pfizer Inc., Novartis International AG, DuPont de Nemours, Inc., and Sanofi S.A.

The ADHD market is a significant and growing market, with total sales reaching over $23 billion in the United States for the 12-months ended November 2023. Stimulants are the most commonly prescribed class of medications for ADHD, accounting for approximately 88% of all ADHD medication prescriptions. However, current treatments have limitations, including the need for multiple doses per day, slow onset of action, and crash/rebound effects.

Cingulate's PTR platform technology has the potential to address these limitations and provide a true once-daily dose with fast onset of action, minimized or eliminated crash/rebound effects, and entire active-day efficacy. The company's product candidates, including CTx-1301, CTx-1302, and CTx-2103, are designed to improve patient compliance and health outcomes in the treatment of ADHD and anxiety.

In terms of commercialization, Cingulate does not currently have any internal sales, marketing, or distribution infrastructure or capabilities. If CTx-1301 and/or CTx-1302 are approved, the company plans to pursue commercialization of its product candidates in the United States, which is expected to be the first country in which it receives market authorization. The company will need a commercial collaboration partner to benefit from their ability to provide a more immediate access to marketing, sales, market access, and distribution infrastructure.

The company's intellectual property portfolio includes patents and patent applications related to its PTR technology, as well as trade secrets and know-how. Cingulate has filed patent applications for its product candidates and has obtained registered trademarks for its brand names.

The company faces competition from pharmaceutical and generic drug companies, including Janssen, Novartis, Takeda, Aytu, Tris, Corium, Ironshore, and Rhodes. The company believes that its product candidates offer the potential to overcome longstanding unmet needs for the majority of ADHD patients.

In terms of government regulation, Cingulate is subject to the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations. The company must comply with good laboratory practices (GLP) and good clinical practices (GCP) in conducting preclinical and clinical studies, respectively. The company must also comply with current good manufacturing practices (cGMP) in manufacturing its product candidates.

The company's product candidates must undergo rigorous preclinical testing, including laboratory evaluations of drug chemistry, formulation, and stability, as well as studies to evaluate toxicity in animals. The company must also conduct clinical trials, including Phase 1, 2, and 3 trials, to evaluate the safety and efficacy of its product candidates.

The company submits its product candidates to the FDA for marketing approval, including payment of application user fees. The FDA reviews the submissions and may request additional information or conduct inspections of the company's manufacturing facilities. The company may also be required to conduct post-approval trials to further evaluate the safety and efficacy of its product candidates.